Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Liabilities (2020 - 2024)

Historic Other Non-Current Liabilities for Puma Biotechnology (PBYI) over the last 5 years, with Q4 2024 value amounting to $121000.0.

  • Puma Biotechnology's Other Non-Current Liabilities changed 0.0% to $121000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $121000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $121000.0 for FY2024, which is 0.0% changed from last year.
  • Puma Biotechnology's Other Non-Current Liabilities amounted to $121000.0 in Q4 2024, which was down 0.0% from $121000.0 recorded in Q3 2024.
  • Puma Biotechnology's 5-year Other Non-Current Liabilities high stood at $26.0 million for Q4 2020, and its period low was $37000.0 during Q2 2022.
  • Over the past 5 years, Puma Biotechnology's median Other Non-Current Liabilities value was $1.0 million (recorded in 2021), while the average stood at $4.9 million.
  • Per our database at Business Quant, Puma Biotechnology's Other Non-Current Liabilities surged by 2081621.62% in 2023 and then crashed by 9843.65% in 2024.
  • Over the past 5 years, Puma Biotechnology's Other Non-Current Liabilities (Quarter) stood at $26.0 million in 2020, then crashed by 96.48% to $915000.0 in 2021, then soared by 707.76% to $7.4 million in 2022, then tumbled by 98.36% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024.
  • Its last three reported values are $121000.0 in Q4 2024, $121000.0 for Q3 2024, and $121000.0 during Q2 2024.